Canaccord’s healthcare analyst Jason Mills weighed in with an optimistic view on Sunshine Heart Inc (NASDAQ:SSH), following the news that the FDA responded to the company’s IDE …
Canaccord Genuity analyst Jason Mills was out pounding the table on Sunshine Heart Inc (NASDAQ:SSH) Thursday, reiterating a Buy rating and a $7.50 price target, which represents a potential …
Canaccord Genuity analyst Jason Mills came out today with a favorable report on Sunshine Heart Inc (NASDAQ:SSH), following the news that the company received unconditional …
In a research note published yesterday, Canaccord analyst Jason Mills reiterated a Buy rating on Sunshine Heart (NASDAQ:SSH) with a $10 price target. …
